“Fabry Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Fabry Disease Market.
The Fabry Disease Pipeline report embraces in-depth commercial, regulatory, and Fabry Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Fabry Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Fabry Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Fabry Disease treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Fabry Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Fabry Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Fabry Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Fabry Disease therapeutics market.
Fabry Disease Therapeutics Landscape
There are approx. 18+ key companies developing therapies for Fabry Disease. Currently, Protalix Biotherapeutics is leading the therapeutics market with its Fabry Disease drug candidates in the most advanced stage of clinical development.
Fabry Disease Companies Actively Working in the Therapeutic Market Include:
Idorsia Pharmaceuticals
Protalix
Sanofi Genzyme
Sangamo Therapeutics
4D Molecular Therapeutics
Resverlogix Corp
AVROBIO
Freeline Therapeutics
Ozmosis Research Inc.
CellGenTech, Inc.
uniQure
Codexis
Canbridge
Eleva GmbH
MP6 therapeutics
Amicus therapeutics
Sigilon Therapeutics
And Many Others
Emerging and Marketed Fabry Disease Drugs Covered in the Report Include:
Pegunigalsidase Alfa: Protalix Biotherapeutics
Venglustat: Sanofi
4D 310: 4D Molecular Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Fabry Disease Companies Working in the Market @
https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight
Analysis of Emerging Fabry Disease Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Fabry Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Learn How the Fabry Disease Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Fabry Disease Treatment Patterns
4. Fabry Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fabry Disease Late Stage Products (Phase-III)
7. Fabry Disease Mid-Stage Products (Phase-II)
8. Fabry Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fabry Disease Discontinued Products
13. Fabry Disease Product Profiles
14. Major Fabry Disease Companies in the Market
15. Key Products in the Fabry Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Fabry Disease Unmet Needs
18. Fabry Disease Future Perspectives
19. Fabry Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Atopic Dermatitis Market
“Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Atopic Dermatitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Atopic Dermatitis market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/market-research
